PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Executive Summary
Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.
You may also be interested in...
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.
Where Cholesterol Surrogates Stand After ACC '16
Failure of another CETP inhibitor – Lilly’s evacetrapib – despite robust LDL-lowering raises more doubt about surrogates, yet doesn’t put too much of a damper on PCSK9 inhibitors at the annual American College of Cardiology meeting. Statins get another boost just ahead of entry of Crestor generics.
PCSK9 Sponsors, Payers In The Ring At ACC
Cardiologists bemoaned high cost of new drugs and high hurdles for reimbursement at the American College of Cardiology annual meeting; will outcomes data save the day?